Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHPA regulatory affairs

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble exec Douglas Bierer, PhD, will succeed 18-year Consumer Healthcare Products Association veteran William Soller, PhD, in leading the group's regulatory and scientific affairs department effective May 5. In his position as VP-regulatory & scientific affairs, Bierer will take a leading role in helping CHPA "demonstrate to regulatory bodies the public health benefits of broad consumer access" to OTC products, the association says. Bierer brings over 20 years of experience in the OTC drug area, having served in various roles at P&G since 1979. He worked most recently as director, global regulatory & toxicology for P&G's Personal Health Care Products division. Soller departed CHPA at the end of March to pursue other opportunities...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts